Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024 | Press Releases

CUPERTINO, Calif., Nov. 06, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024 | Press Releases

CUPERTINO, Calif., Oct. 31, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024 | Press Releases

CUPERTINO, Calif., Oct. 08, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024 | Press Releases

CUPERTINO, Calif., Oct. 02, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

Sep 26, 2024 | Press Releases

CUPERTINO, Calif., Sept. 26, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Sep 9, 2024 | Press Releases

– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia – – Additional vocal biomarker data from ongoing open label extension...